Jefferies Financial Group Reiterates Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities researchers at Jefferies Financial Group in a research report issued on Monday,London Stock Exchange reports. They currently have a £175 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target indicates a potential upside of 47.85% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. Citigroup raised their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a research note on Tuesday, July 28th. Finally, Berenberg Bank reiterated a “buy” rating and set a £160 target price on shares of AstraZeneca in a research report on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, AstraZeneca has an average rating of “Moderate Buy” and a consensus price target of £152.17.

AstraZeneca Trading Down 6.3%

Shares of AstraZeneca stock opened at £118.36 on Monday. The company has a market capitalization of £183.56 billion, a P/E ratio of 17.83, a P/E/G ratio of 0.86 and a beta of 0.23. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. The company has a fifty day moving average of £134.04 and a 200 day moving average of £140.23. AstraZeneca has a fifty-two week low of £107.84 and a fifty-two week high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.